Helminth/parasite treatment of multiple sclerosis

Current Treatment Options in Neurology

Volumn 16, Issue 6, 2014, Pages

  Correale, Jorge ^a  

^a FLENI   (Argentina)

Author keywords

Autoimmune diseases; Autoimmunity; EAE; Environmental factors; Helminth; Helminth therapy; Hygiene hypothesis; Immunoregulation; Infections; Multiple sclerosis; Necator americanus; Parasite; Treatment; Trichura suis

Indexed keywords

DNA VACCINE; GAMMA INTERFERON; GLYCOPROTEIN; GLYCOPROTEIN ES 62; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 4; INTERLEUKIN 5; MYELIN BASIC PROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; NITRIC OXIDE; PLACEBO; PROTEOLIPID PROTEIN; UNCLASSIFIED DRUG;

ALTERNATIVE MEDICINE; ANTIINFLAMMATORY ACTIVITY; ASCARIS LUMBRICOIDES; AUTOIMMUNE DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); DENDRITIC CELL; ENTEROBIUS VERMICULARIS; EXPERIMENTAL ANIMAL; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FASCIOLA HEPATICA; FOLLOW UP; HELMINTHIASIS; HUMAN; HYMENOLEPIS NANA; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOREGULATION; MOUSE MODEL; MULTIPLE SCLEROSIS; NECATOR AMERICANUS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARASITOSIS; PATIENT MONITORING; PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; REVIEW; SCHISTOSOMA MANSONI; STRONGYLOIDES STERCORALIS; STRONGYLOIDES VENEZUELENSIS; TH1 CELL; TH2 CELL; THERAPY WITH HELMINTHS; THERAPY WITH PARASITE; TRICHINELLA PSEUDOSPIRALIS; TRICHINELLA SPIRALIS; TRICHURIS SUIS; TRICHURIS TRICHIURA;

EID: 84899068251     PISSN: 10928480     EISSN: 15343138     Source Type: Journal    
DOI: 10.1007/s11940-014-0296-3     Document Type: Review

References (71)

1. McFarland H, Martin R. Multiple Sclerosis: a complicated picture of autoimmunity. Nat Immunol. 2007;8:913-9. (Pubitemid 47300005)
2. Marrie RA. Environmental risk factors in multiple sclerosis. Lancet Neurol. 2004;3:709-18. (Pubitemid 39535256)
3. Oksenberg JR, Baranzini SE, Sawcer S, Hauser SL. The genetics of multiple sclerosis: SNP to pathways to pathogenesis. Nat Rev Genet. 2008;9:516-26. (Pubitemid 351861542)
4. Gourraud PA, Harbo HF, Hauser SL, Baranzini SE. The genetics of multiple sclerosis: an up-to-date review. Immunol Rev. 2012;248:87-103.
5. Ebers GC, Bulman DE, Sadovnik AD, Paty DW, Warren S, Hader W, et al. A population-based study of multiple sclerosis in twins. N Engl J Med. 1986;315:1638-42. (Pubitemid 17052896)
6. Rosati G. The prevalence of multiple sclerosis in the world: an update. Neurol Sci. 2011;22:117-39.
7. Alter M, Kahana E, Lowenson R. Migration and risk of multiple sclerosis. Neurology. 1978;28:1089-93. (Pubitemid 9012847)
8. Ascherio A. Environmental factors in multiple sclerosis. Expert Rev Neurother. 2013;13 Suppl 12:3-9.
9. Christen U, von Herrath MG. Infections and autoimmunity-good or bad? J Immunol. 2005;174:7481-6.
10. Correale J, Fiol M, Gilmore W. The risk of relapses in multiple sclerosis during systemic infections. Neurology. 2006;67:652-9. (Pubitemid 44273613)
11. Bach JF. The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med. 2002;347:911-20.
12. Leibowitz U, Atanovsky A, Medalie JM, Smith HA, Halpern L, Alter M. Epidemiological study of multiple Sclerosis in Israel. II. Multiple sclerosis and the level of sanitation. J Neurol Nurosurg Psychiatry. 1966;29:60-8.
13. Fleming JO, Cook TD. Multiple sclerosis and the hygiene hypothesis. Neurology. 2006;67:2085-6. (Pubitemid 44967402)
14. van den Bigeelar AH, Rodrigues LC, van Ree R, van der Zee JS, Hoeksma-Kruize YC, Souverijn JH, et al. Long-term treatment of intestinal helminthes increases mite skin-test reactivity in Gabonese schoolchildren. J Infect Dis. 2004;189:892- 900.
15. • Correale J, Farez M. The impact of parasite infections on the course of multiple sclerosis. J Neuroimmunol. 2011;233:6-11. This paper clearly showed that helminths were indeed contributing to improve symptoms in MS patients, as clearance of parasites resulted in increased
16. •• McSorley HJ, Maizels RM. Helminth Infections and host immune regulation. Clin Microbiol Rev. 2012;25:585-608. This is an excellent review documenting how helminth infections modulate immune responses of the host, and describing the development of therapeutic possibilities from the study of helminth infections severity of symptoms
17. • Maizels RM, Hewitson JP, Smith KA. Susceptibility and immunity to helminth parasites. Curr Opin Immunol. 2012;24:459-66. This paper describes the orchestration of different immunological pathways involved in susceptibility and immunity to helminth parasites
18. Maizels RM, Yazdanbakhsh M. T-cell regulation in helminth parasite infections:implications for inflammatory diseases. Chem Immunol Allergy. 2008;94:112-23.
19. Koyasu S, Moro K, Tanabe M, Takeuchi T. Natural helper cells: a new player in the innate response against helminth infection. Adv Immunol. 2010;108:21-44.
20. Saenz SA, Siracusa MC, Perrigoue SP, Urban Jr JF, Tocker JE, Budelsky AL, et al. IL-25 elicits a multipotent progenitor cell population that promotes TH2 cytokine responses. Nature. 2010;464:1362-6.
21. Artis D, Grencis RK. The intestinal epithelium: sensors to effectors in nematode infection. Mucosal Immunol. 2008;1:252-64. (Pubitemid 351850532)
22. Yazdanbakhsh M, Kremsner PG, van Ree R. Allergy, parasites and the hygiene hypothesis. Science. 2002;19:490-4.
23. Pinelli E, Brandes S, Dormans J, Gremmer E, van Loveren H. Infection with the roudworn Toxocara canis leads to exacerbation of experimental allergic airway inflammation. Clin Exp Allergy. 2008;38:649-58. (Pubitemid 351406060)
24. Maizels RM, Balic A, Gomez-Escobar N, Nair M, Taylor MD, Allen JE. Helminth parasites-masters of regulation. Immunol Rev. 2004;201:89-116.
25. Sartono E, Kruize YCM, KUrniawan-Atmadja A, Maizels RM, Yazdanbakhsh M. Depression of antigen-specific interleukin-5 and interferon-γ responses in human lymphatic filariasis as a function of clinical satus and age. J Infect Dis. 1997;175:1276-80. (Pubitemid 27176529)
26. Kurniawan A, Yazdanbakhsh M, van Ree R, Aalberse R, Selkirk ME, Partono F, et al. Differential expression of IgE and IgG4 specific antibody responses in asymptomatic and chronic human filariasis. J Immunol. 1993;150:3941-50. (Pubitemid 23129776)
27. Satoguina JS, Adjobimey T, Arndts K, Hoch J, Oldenburg J, Layland LE, et al. Tr1 and naturally occurring regulatory T cells induce IgG4 in B cells through GITR/GITR-L interaction, IL-10 and TGF-β. Eur J Immunol. 2008;38:3101-13.
28. La Flamme AC, Ruddenklau K, Bäckström BT. Schistosomiasis decreases central nervous system inflammation and alters the progression of experimental autoimmune encephalomyelitis. Infect Immun. 2003;71:4996-5004. (Pubitemid 37070742)
29. Sewell D, Qing Z, Reinke E, Elliot D, Weinstock J, Sandor M, et al. Immunomodulation of experimental autoimmune encephalomyelitis by helminth ova immunization. Int Immunol. 2003;15:59-69. (Pubitemid 36163769)
30. Walsh KP, Brady MT, Finlay CM, Boon L, Mills KH. Infection with a helminth parasite attenuates autoimmunity through TGF-beta-mediated suppression of Th17 and Th1 responses. J Immunol. 2009;183:1577-86.
31. Gruden-Movsesijan A, Illic N, Mostarica-Stojkovic M, Stosic-Grujicic S, Milic M, Sofronic-Milosavljevic L. Mechanisms of modulation of experimental autoimmune encephalomyelitis by chronic Trichinella spiralis infection in dark agouti rats. Parasite Immunol. 2010;32:450-9.
32. Wilson MS, Taylor MD, O'Gorman MT, Balic A, Barr TA, Filbery K, et al. Helminth-induced CD19+CD23hi B cells modulate experimental allergic and autoimmune inflammation. Eur J Immunol. 2010;40:1682-96.
33. Zaccone P, Fehervari Z, Jones FM, Sidobre S, Kronenberg M, Dunne DW, et al. Schistosoma mansoni modulate the activity of the innate immune response and prevent onset of type 1 diabetes. Eur J Immunol. 2003;33:1439-49. (Pubitemid 36609163)
34. Osada Y, Shimizu S, Kumagai T, Yamada S, Kanazawa T. Schistosoma mansoni infection reduces severity of collagen-induced arthritis via down-regulation of por-inflammatory mediators. Int J Parasitol. 2009;39:457-64.
35. Elliott DE, Li J, Blum A, Metwali A, Qadir K, Urban JF, et al. Exposure to schistosome eggs portects mice from TNBS-induced colitis. Am J Physiol Gastrointest Liver Physiol. 2003;284:G385-91. (Pubitemid 36227886)
36. Khan WI, Blennerhasset PA, Varghese AK, Chowdhury SK, Omsted P, Deng Y, et al. Intestinal nematode infection ameliorates experimental colitis in mice. Infect Immun. 2002;70:5931-7. (Pubitemid 35192680)
37. Kuijk LM, Klaver EJ, Kooij G, van der Pol SM, Heijnen P, Bruijns SC, et al. Soluble helminth products suppress clinical signs in murine experimental autoimmune encephalomyelitis and differentially modulate human dendritic cell activation. Mol Immunol. 2012;51:210-8.
38. Chiuso-Minicucci F, VAN DB, Zorzella-Pezavento SF, Peres RS, Ishikawa LL, Rosa LC, et al. Experimental autoimmune encephalomyelitis evolution was not modified by multiple infections with Strongyloides venezuelensis. Parasite Immunol. 2011;33:303-8.
39. Reyes JL, Espinoza-Jimenens AF, Gonzalez MI, Verdin L, Terrazas LI. Taenia crassiceps infection abrogates experimentala utoimmune encephalomyelitis. Cell Immunol. 2011;267:77-87.
40. Wu Z, Nagano I, Asano K, Takahashi Y. Infection of non-encapsualted species of Trichinella ameliorates experimental autoimmune encephalomyelitis involving suppression of Th17 and Th1 response. Parasitol Res. 2010;107:1173-88.
41. Zheng X, Hu X, Zhou G, Lu Z, Qiu W, Bao J, et al. Soluble egg antigen from Schistosoma japonicum modulates the progression of chronic progressive experimental autoimmune encephalomyelitis via Th2-shift response. J Neuroimmunol. 2008;194:107-14.
42. Zhu B, Trikudanathan S, Zozulya AL, Sandoval- Garcia C, Kennedy JK, Atochina O, et al. Immune modulation by Lacto-N-fucopentaose III in experimental autoimmune encephalomyelitis. Clin Immunol. 2012;142:351-61.
43. Hasseldam H, Hansen CS, Johansen FF. Immunomodulatory effects of helminths and protozoa in multiple sclerosis and experimental autoimmune encephalomyelitis. Parasite Immunol. 2013;35:103-8.
44. Hunter MM, Wang A, Hirota CL, McKay DM. Helminth infection enhances disease in a murine TH2 model of colitis. Gastroenterology. 2007;132:1320-30. (Pubitemid 46627574)
45. Correale J, Farez M. Association between parasite infection and immune responses in multiple sclerosis. Ann Neurol. 2007;61:97-108. (Pubitemid 46363837)
46. Correale J, Farez M, Razzitte G. Helminth infections associated with multiple sclerosis induce regulatory B cells. Ann Neurol. 2008;64:187-99.
47. Bager P, Arnved J, Rønborg S, Wohlfahrt J, Poulsen LK, Westergaard T, et al. Trichuris suis ova therapy for allergic rhinitis: a randomized, double-blind, place-bo- controlled clinical trial. J Allergy Clin Immunol. 2010;125:123-30.
48. Summers RW, Elliot DE, Urban Jr JF, Thompson RA, Weinstrock JV. Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial. Gastroenterology. 2005;128:825-32. (Pubitemid 40523535)
49. Summers RW, Elliott DE, Urban Jr JF, Thompson R, Weinstrock JV. Trichuris suis therapy in Crohn 's disease. Gut. 2005;54:87-90. (Pubitemid 40007223)
50. .• Fleming JO, Isaak A, Lee JE, Luzzio CC, Carrithers MS, Cook TD, et al. Probiotic helminth administration in relapsing-remitting multiple sclerosis: a phase 1 study. Mult Scler. 2011;17:743-54. This paper describes the first human study using Trichura suis ova in relapsing remitting multiple sclerosis. Treatment was well-tolerated and favorable trends were observed in MRI and immunological assessments
51. Daveson AJ, Jones DM, Gaze S, McSorley H, Clouston A, Pascoe A, et al. Effect of hookworm infection on wheat challenge in celiac disease-a randomised double-blinded placebo controlled trial. PLos ONE. 2011;6:e17366.
52. Graepel R, Leung G, Wang A, Villemaire M, Jirik FR, Sharkey KA, et al. Murine autoimmune arthritis is exaggerated by infection with the rat tapeworm, Hymenolepis diminuta. Int J Parasitol. 2013;43:593-601.
53. •• Fleming JO. Helminth therapy in multiple sclerosis. Int J Parasitol. 2013;43:259-74. This is an excellent review on helminth therapy in multiple sclerosis
54. Tilp C, Kapur V, Loging W, Erb KJ. Prerequisites for the pharmaceutical industry to develop and commercialise helminthes and helminth-derived product therapy. Int J Parasitol. 2013;43:319-25.
55. Voldsgaard A, Bager P, Kapel C, Roepstorff A, Thamsborg S, Soendergaard H, et al. Trichuris suis ova therapy for relapsing Multiple Sclerosis- A safety study. Neurology. 2012;78:S30.005.
56. Benzel F, Erdur H, Kholer S, Frentsch M, Thiel A, Harms L, et al. Immune monitoring of trichuris suis egg therapy in multiple sclerosis patients. J Helminthol. 2012;86:339-47.
57. Fleming J, Isaak A, Hardin LV, Huston J, Boland J, Broman AT, et al. Temporal changes in MRI activity, inflammation, immunomodualtion and gene expression in relapsing-remitting multiple sclerosis subjects treated with helminth probiotic Trichuris suis . Neurology. 2012;78:S30.004.
58. Rosche B, Wernecke KD, Ohlaraun S, Dörr JM, Paul F. Trichuris suis ova in relapsing-remitting multiple sclerosis and clinically isolated syndrome (TRIONS): study protocol for a randomized controlled trial. Trials. 2013;14:112. doi:10.1186/1745-6215-14-112.
59. Mortimer K, Brown A, Feary J, Jagger C, Lewis S, Antoniak M, et al. Dose.ranging study for trials of therapeutic infection with Necator americanus in humans. Am J Trop Med Hyg. 2006;75:914-20. (Pubitemid 351627540)
60. Elias D, Akuffo H, Pawlowski A, Haile M, Schön T, Britton S. Schistosoma mansoni infection reduces the protective efficacy of BCG vaccination against virulent Mycobacterium tuberculosis . Vaccine. 2005;23:1326-34. (Pubitemid 40127324)
61. Cruz-Chan JV, Rosado-Vallado M, Dumonteil E. Malaria vaccine efficacy: overcoming the helminth hurdle. Exp Rev Vaccines. 2010;9:707 -11.
62. Sabin EA, Araujo MI, Carvalho EM, Pearce EJ. Impairment of tetanus toxoid-specific Th1-like immune responses in human infected with Schistosoma mansoni. J Infect Dis. 1996;173:269-72. (Pubitemid 26006833)
63. Bassily S, Hyams N, El-Ghorab M, Mansour MM, El-Masry NA, Dunn MA. Immunogenicity of hepatitis B vaccine in patients infected with Schistosoma mansoni. Am J Trop Med Hyg. 1987;36:549-53. (Pubitemid 17099469)
64. Shin J, Gardiner GW, Deitel W, Kandel G. Does whipworm increase the pathogenicity of Campylobacter jejuni? A clinical correlate of an experimental observation. Can J Gastroenterol. 2004;18:175-7. (Pubitemid 38477235)
65. Mansfield LS, Gauthier DT, Abner SR, Jones KM, Wilder SR, Urban JF. Enhancement of disease and pathology by synergy of Trichuris suis and Campylobacter jejuni in the colon of immunologically naive swine. Am J Trop Med Hyg. 2003;63:70- 80.
66. Wolff MJ, Braodhurst MJ, Loke P. Helminthic therapy: improving mucosal barrier function. Trends Parasitol. 2012;28:187-94.
67. Reddy A, Fried B. An update on the use of helminths to treat Crohn's and other autoimmune diseases. Parasitol Res. 2009;104:217-21.
68. Johnston MJG, MacDonald JA, McKay DM. Parasitic helminthes: a pharmacopeia of anti-inflammatory molecules. Parasitology. 2009;136:125-47.
69. Danilowiz-Luebert E, O'Regan NL, Steinfelder S, Hartmann S. Modulation of specific and allergy-related immune responses by helminths. J Biomed Biotechnol. 2011;2011:821578.
70. Pineda MA, McGrath MA, Smith PC, Al-Riyami L, Rzepecka J, Gracie JA, et al. The parasitic helminth product ES-62 suppresses pathogenesis in collagen-induced arthritis by targeting the interleukin-17-producing cellular network at multiple sites. Arthritis Rheum. 2012;64:3168-78.
71. Imai S, Tezuka H, Fujita K. A factor inducing IgE from a filarial parasite prevents insulin-dependent diabetes mellitus in nonobese diabetic mice. Biochem Biophys Res Commun. 2001;286:1051-8. (Pubitemid 32924878)